Cellectar Biosciences Inc (CLRB)

• $2.06

  $2.15

  $2.08
  

  0.96%

  Downside

  Day's Volatility :4.19%

  Upside

  3.26%

  
• $1.82

  $4.45

  $2.08
  

  12.5%

  Downside

  52 Weeks Volatility :59.1%

  Upside

  53.26%

  

Returns

What analysts predicted

Upside of 505.77%

• AIGH Capital Management, LLC

  8.47%

• Rosalind Advisors, Inc.

  7.55%

• Nantahala Capital Management, LLC

  5.11%

• Vanguard Group Inc

  4.36%

• ADAR1 Capital Management LLC

  1.90%

• Barclays PLC

  0.94%

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p